Skip to content
NASDAQ · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES · SMALL CAP

Insight Molecular Diagnostics Inc. IMDX

12 fiscal years on record · USD · FY2025 reported · SEC filings only
$4.1M
▲ 115.6% YoY
$-50.2M
$-25.4M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 4.1M
Revenue, FY2025 · full 12-year series below
Revenue $M Net income $M
FY2025 · Revenue 4.1 · Net income -50.2
-30M-60M
20142017202020232025
Compound annual growth
+61.8%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−1239 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -1260.8%
-1000%-2000%-3000%
201420192025
ROE
FY2023 · ROE -101.5%
-200%-400%
201420192025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.
Gross margin56.7%
Operating margin-1260.8%
Net margin-1238.5%
EBITDAUSD -48.9M

Return on equity has no reading this year — return on capital employed, just below, still does: -246%.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -25.4
-20M-40M
201420192025

Total assetsUSD 25.8M
EquityUSD -31.5M
CashUSD 11.6M
Current ratio1.27×

Equity funds -122% of total assets.

The 12-year record

12 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
IMDX, 12-year financial record
Metric 202520242023202220212020201920182017201620152014
Revenue $B0.00.00.00.00.00.0◌◌◌◌◌◌
Operating income $B−0.1−0.1−0.0−0.0−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.1−0.0−0.0−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B0.00.00.0◌−0.0−0.0◌◌◌◌◌◌
Net income $B−0.1−0.1−0.0−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−1.65−4.66−3.75−13.25−0.72−0.46−0.44−0.42−0.64−0.42−0.42−0.27
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend————————————
ROE %——−101.5−146.5−129.9−93.1−130.9−402.6−271.6−110.1——
Shares out B0.030.020.010.120.090.070.060.040.030.030.03◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures · 4 divergences in 52 reconciliationsAUDITED

Reconciled in 8 of the 12 fiscal years we could check. 4 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 16 checks were skipped: the balance sheet is not tagged before 2015. 13 checks were skipped: revenue is not tagged before 2020. Seven checks were skipped: EPS is not tagged before 2014.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures4 divergent
ActivityIn Vitro & In Vivo Diagnostic Substances
Listed onNASDAQ
Incorporated inCalifornia
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2014

Share this section

Download image